Skip to main content
Clinical Trials/NCT04764708
NCT04764708
Completed
Not Applicable

Compassion and Metacognition Based Therapy for Schizotypal Personality Disorder: A Pilot Non-inferiority Randomized Controlled Trial on Repeated Measures.

Tages Onlus1 site in 1 country16 target enrollmentDecember 15, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizotypal Personality Disorder
Sponsor
Tages Onlus
Enrollment
16
Locations
1
Primary Endpoint
Change from Baseline Personality Pathology at 8 months
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to assess the safety and efficacy of a newly developed psychotherapy for schizotypal personality disorder. This new form of psychotherapy integrates compassion focused therapy and metacognitively oriented psychotherapy.

Detailed Description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a psychological assessment so as to determine eligibility for study entry. Patients who meet the eligibility requirements will be randomized in a double-blind manner in a 1:1 ratio to new integrative psychotherapy or treatment as usual (cognitive behavioral therapy plus standard psychopharmacological treatment). One month after the conclusion of the two forms of treatment (both lasting 6 months), patients will have access to the final follow-up assessment.

Registry
clinicaltrials.gov
Start Date
December 15, 2020
End Date
December 20, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Tages Onlus
Responsible Party
Principal Investigator
Principal Investigator

Simone Cheli

Principal Investigator

Tages Onlus

Eligibility Criteria

Inclusion Criteria

  • Being diagnosed with Schizotypal Personality Disorder at SCID-5-AMPD

Exclusion Criteria

  • Being under psychotherapy or psychopahrnacological treatment
  • Being diagnosed with schizophrenia and other psychotic disorders
  • Being diagnosed with bipolar disorder
  • Being diagnosed with intelletual disability
  • Being diagnosed with any neurological disases

Outcomes

Primary Outcomes

Change from Baseline Personality Pathology at 8 months

Time Frame: 9 measurements over the course of 8 months: (i) at 1 month before intervention starts; (ii) once the treatment starts; (iii) 6 measurements at the end of each month of intervention; iv) at 1-month follow-up.

Decrese of Personality Inventory for DSM-5 - Brief Form (PID-5-BF) total score (with a range of 0 to 75; higher scores indicating a more severe psychopathology) from baseline to final assessment after 8 months.

Secondary Outcomes

  • Schizotypal Personality Disorder Diagnosis (SPD)(Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment.)
  • General Psychopathology(Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment.)
  • Metacognition(Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment.)

Study Sites (1)

Loading locations...

Similar Trials